9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $190M | -$196539 | 89.7% | -101.2% | -$117M | $108M | $54M |
| 2024 | $130M | -$260602 | 89.7% | -204.0% | -$114M | $110M | $89M |
| 2023 | $77M | -$184678 | 88.0% | -238.1% | -$136M | $106M | $60M |
| 2022 | $24M | -$181119 | 91.0% | -757.9% | -$174M | — | $128M |
| 2021 | $3M | -$69612 | 81.0% | -5391.9% | -$146M | — | $59M |
| 2020 | — | -$134M | — | — | -$122M | — | $101M |
| 2019 | — | -$141M | — | — | -$126M | — | $62M |
| 2018 | — | -$74M | — | — | -$63M | — | $50M |
| 2017 | — | -$34M | — | — | -$30M | — | $34M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $60M | -$56M | 88.1% | -87.1% | — | $108M | $62M |
| Dec '25 | $57M | -$48M | 91.6% | -82.2% | — | $108M | $54M |
| Sep '25 | $51M | -$53M | 89.3% | -102.6% | — | $109M | $52M |
| Jun '25 | $49M | -$47M | 88.6% | -93.4% | — | $110M | $136M |
| Mar '25 | $33M | -$49M | 88.8% | -143.7% | — | $110M | $106M |
| Dec '24 | $42M | -$43M | 90.9% | -98.6% | — | $110M | $89M |
| Sep '24 | $33M | -$44M | 88.5% | -132.0% | — | — | $48M |
| Jun '24 | $29M | -$32M | 89.9% | -139.2% | — | — | $162M |
| Mar '24 | $26M | -$141M | 89.2% | -538.7% | — | — | $53M |
| Dec '23 | $24M | -$42M | 86.7% | -170.3% | -$29M | $106M | $60M |
| Sep '23 | $23M | -$44M | 89.3% | -195.3% | -$29M | — | $65M |
| Jun '23 | — | -$47M | — | — | -$41M | — | $116M |
| Mar '23 | — | -$52M | — | — | -$36M | — | $110M |
| Dec '22 | — | -$42M | — | — | -$34M | — | $128M |
| Sep '22 | — | -$41M | — | — | -$47M | $73M | $185M |
| Jun '22 | — | -$45M | — | — | -$39M | $34M | $113M |
| Mar '22 | — | -$53M | — | — | -$54M | — | $79M |
| Dec '21 | — | -$43M | — | — | -$41M | — | $59M |
| Sep '21 | — | -$35M | — | — | -$40M | — | $92M |
| Jun '21 | — | -$35M | — | — | -$32M | — | $69M |
How the market has priced RYTM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Rhythm Pharmaceuticals, Inc.'s revenue has grown 178.5% per year. These are computed facts, not advice.
As of FY2025, Rhythm Pharmaceuticals, Inc. reported $108M of total debt against $54M of cash; operating income covered interest expense -9.3×.
In FY2025, gross margin was 89.7%, operating margin -101.2%, and net margin -0.1%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.